Novadaq's OPTTX for AMD (age-related macular degeneration):
This article was originally published in Clinica
Executive Summary
Novadaq Technologies has CE-marked for sale in Europe what it claims is the first commercially available tool that can diagnose, treat and manage wet age-related macular degeneration (AMD) in a single device. The OPTTX system produces ultra high-speed indocyanine green angiograms and facilitates the identification of choroidal feeder vessels (FVs). It also allows the physician to view a real-time angiogram, in which a treatment laser is able to track and fire precisely while the FV is visible. It then enables the physician to immediately confirm the effectiveness of the treatment. Conventional feeder vessel therapy for the condition uses two medical devices, one for imaging, and the second for treatment, explained the Toronto, Canada firm. Novadaq is conducting a limited launch of the OPTTX system, and plans full commercialisation in the second quarter of 2007.